Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2009 Aug;31(8):561–570. doi: 10.1097/MPH.0b013e3181a6e043

Figure 1.

Figure 1

Growth and Serial Passage of ASPS Xenograft Tumors in Immunocompromised NOD.SCID\NCr Mice. ASPS tumor fragments (1-2 mm) were implanted subcutaneously in NOD.SCID\NCr immunocompromised mice within 24 hours following patient surgery as described in Materials and Methods. Tumors were harvested at the indicated times and serially passaged.